Feature | May 12, 2014

Remote Patient Management Study Demonstrates Significant Reduction in Mortality and Hospitalization

PREDICt-RM collaborative study highlights improved outcomes in ICD and CRT-D patients followed with Latitude system


May 12, 2014 — Patients using the Boston Scientific Latitude remote patient management system with wireless telemetry demonstrated significantly lower mortality and fewer hospitalizations than patients with Latitude-compatible devices who were not followed on the system, according to results from the PREDICt-RM study (Patient RElated Determinants of ICD Remote Monitoring Utilization and Outcomes). The results were presented at Heart Rhythm 2014, the Heart Rhythm Society's (HRS) 35th annual scientific sessions in San Francisco.

PREDICt-RM demonstrated a 33 percent relative reduction in the risk of death in patients with Boston Scientific ICDs (implantable cardioverter-defibrillators) and CRT-Ds (cardiac resynchronization therapy devices) who were remotely monitored via Latitude, compared to patients who were not remotely monitored. Additionally, these patients experienced a 19 percent relative reduction in hospitalizations for any cause. The study outcomes were presented by Joseph Akar, M.D., Ph.D., associate professor of medicine at Yale University and the Center for Outcomes Research and Evaluation (CORE) in New Haven, Conn., and are a result of collaboration between Yale CORE, the American College of Cardiology (ACC) and Boston Scientific.

"The PREDICt-RM results demonstrate improved outcomes for those ICD and CRT-D patients using the Latitude wireless remote patient management system," said Akar. "Despite the widespread availability of this technology, we know that it is underutilized. Our hope is that this study may inform clinical practice guidelines and promote the routine use of this technology in daily practice."

PREDICt-RM’s results were made possible via a unique research design that linked three large healthcare databases, illuminating the potential for "big data" and healthcare analytics to advance patient care. PREDICt-RM combined the National Cardiovascular Data Registry (NCDR) from ACC, CMS data from Medicare, and the Boston Scientific Latitude system. 

"No single database could have answered this question effectively. Through an innovative collaboration with ACC and Boston Scientific, we were able to leverage the strengths of each database to develop a deeper understanding of the association of remote monitoring with patient outcomes. We believe the PREDICt-RM experience should serve as a model for this type of investigation," said Jeptha Curtis, M.D., associate professor of medicine at Yale University and CORE.

"PREDICt-RM demonstrates that wireless remote monitoring using the Latitude system provides a significant benefit to patients and the overall healthcare system," said Kenneth Stein, M.D., chief medical officer, Rhythm Management, Boston Scientific. "We are very excited to have such strong data demonstrating substantially improved survival and reduced hospitalization rates in the patients followed on Latitude."

The Latitude remote patient management system connects a home communicator to the patient's implanted Boston Scientific device through wireless telemetry, enabling automatic collection of patient data. The system capabilities include transmitting physiologic data, as well as data gathered from the implanted device to the healthcare team's Latitude website. The Latitude system is the only implanted-device monitoring system with integrated physiologic monitoring of weight and blood pressure in the United States.

For more information: www.bostonscientific.com


Related Content

News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
Subscribe Now